v3.26.1
Condensed Consolidated Statements of Stockholders' Deficit - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Treasury Stock
Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 29, 2024   32,646          
Beginning balance at Dec. 29, 2024 $ (414,216) $ 493 $ 452,449 $ (8,456) [1] $ 241,717 $ (1,115,729) $ 15,310
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) [2] 18,962       18,753   209
Other comprehensive income (loss), net of tax 2,489     2,489 [1]      
Dividends on common stock (30,549)   53   (30,602)    
Exercise of stock options (in shares)   9          
Exercise of stock options 397   397        
Stock-based compensation expense 7,493   7,493        
Issuance of restricted stock (in shares)   110          
Issuance of restricted stock (15)   (5,606)     5,591  
Tax effect of restricted stock awards (in shares)   (27)          
Tax effect of restricted stock awards (1,208)   (1,208)        
Distributions to noncontrolling interests (276)           (276)
Other (in shares)   15          
Other 169   (791)     960  
Ending balance (in shares) at Jun. 29, 2025   32,753          
Ending balance at Jun. 29, 2025 (416,754) $ 493 452,787 (5,967) [1] 229,868 (1,109,178) 15,243
Beginning balance (in shares) at Mar. 30, 2025   32,728          
Beginning balance at Mar. 30, 2025 (416,809) $ 493 449,625 (7,540) [1] 235,794 (1,110,306) 15,125
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) [2] 9,649       9,531   118
Other comprehensive income (loss), net of tax 1,573     1,573 [1]      
Dividends on common stock (15,433)   24   (15,457)    
Exercise of stock options (in shares)   9          
Exercise of stock options 397   397        
Stock-based compensation expense 3,824   3,824        
Issuance of restricted stock (in shares)   7          
Issuance of restricted stock (15)   (391)     376  
Tax effect of restricted stock awards (in shares)   (3)          
Tax effect of restricted stock awards (88)   (88)        
Other (in shares)   12          
Other 148   (604)     752  
Ending balance (in shares) at Jun. 29, 2025   32,753          
Ending balance at Jun. 29, 2025 $ (416,754) $ 493 452,787 (5,967) [1] 229,868 (1,109,178) 15,243
Beginning balance (in shares) at Dec. 28, 2025 32,800 32,801          
Beginning balance at Dec. 28, 2025 $ (433,666) $ 493 457,112 (6,452) [3] 210,763 (1,106,666) 11,084
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) [4] 15,501       15,788   (287)
Other comprehensive income (loss), net of tax 735     735 [3]      
Dividends on common stock (31,220)   34   (31,254)    
Stock-based compensation expense 7,466   7,466        
Issuance of restricted stock (in shares)   152          
Issuance of restricted stock 2   (6,881)     6,883  
Tax effect of restricted stock awards (in shares)   (50)          
Tax effect of restricted stock awards (1,584)   (1,584)        
Distributions to noncontrolling interests (17)           (17)
Other (in shares)   15          
Other $ 509   (439)     948  
Ending balance (in shares) at Jun. 28, 2026 32,900 32,918          
Ending balance at Jun. 28, 2026 $ (442,274) $ 493 455,708 (5,717) [3] 195,297 (1,098,835) 10,780
Beginning balance (in shares) at Mar. 29, 2026   32,898          
Beginning balance at Mar. 29, 2026 (438,435) $ 493 453,945 (5,953) [3] 202,601 (1,100,206) 10,685
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) [4] 8,628       8,533   95
Other comprehensive income (loss), net of tax 236     236 [3]      
Dividends on common stock (15,821)   16   (15,837)    
Stock-based compensation expense 3,057   3,057        
Issuance of restricted stock (in shares)   22          
Issuance of restricted stock 2   (1,068)     1,070  
Tax effect of restricted stock awards (in shares)   (7)          
Tax effect of restricted stock awards (205)   (205)        
Other (in shares)   5          
Other $ 264   (37)     301  
Ending balance (in shares) at Jun. 28, 2026 32,900 32,918          
Ending balance at Jun. 28, 2026 $ (442,274) $ 493 $ 455,708 $ (5,717) [3] $ 195,297 $ (1,098,835) $ 10,780
[1] At June 29, 2025, the accumulated other comprehensive loss of $5,967 was comprised of net unrealized foreign currency translation loss of $5,485 and net unrealized loss on the interest rate swap agreements of $482.
[2] Net income to the Company for the three and six months ended June 29, 2025 excludes $22 and $52 allocable to the redeemable noncontrolling interests for our joint venture arrangements.
[3] At June 28, 2026, the accumulated other comprehensive loss of $5,717 was comprised of net unrealized foreign currency translation loss of $6,096 and net unrealized gain on the interest rate swap agreements of $379.
[4] Net income to the Company for the three and six months ended June 28, 2026 excludes $72 and $137 allocable to the redeemable noncontrolling interests for our joint venture arrangements.